Knowledge library
This feasibility study examines the build and operation of a state-of-the-art sterile biopharmaceutical injectable manufacturing plant in Akuse, Ghana. Commissioned by Quintex and developed by a consulting consortium consisting of AMPC International Health Consultants, IQVIA, and PwC Ghana, the proposed facility aims to address local medicine shortages and reduce the country’s heavy 70% reliance on imported pharmaceuticals. The plant is designed to focus on Small Volume Parenterals (SVPs), specifically producing generic and branded liquid medications in vials and prefilled syringes while strictly adhering to global Good Manufacturing Practices (GMP) and environmental standards.
Ghana’s pharmaceutical market is entering a pivotal phase. As demand for quality-assured medicines rises, so does demand for greater local and regional production. Upholding current Good Manufacturing Practices (cGMP) is central to this growth.
This playbook is a tool for chief executive officers (CEOs), chief operating officers (COOs), and business leaders making critical strategic investment decisions. The playbook provides:
A business-oriented roadmap for achieving and sustaining cGMP compliance
Guidance on sequencing investments in people, systems, and facilities
A structured framework for choosing between retrofit, brownfield, and greenfield facility strategies
Practical insights from comparable African manufacturers
The potential of the herbal medicine sector to contribute to Ghana’s economic growth cannot be overstated, as the global market value of herbal medicines is projected to reach US$ 5 trillion in 2050.
The packaging sector in Ghana holds immense potential for job creation and economic development. Expanding and establishing local packaging facilities will create direct employment opportunities in manufacturing, R&D, and logistics.